Boehringer Ingelheim celebrates its ‘uniqueness’ by championing both human and animal health in new campaign 

Ingelheim, Germany, 3 April 2019: - Boehringer Ingelheim shows commitment for both human and animal health with the launch of  ‘A Unique Bond’. 

With 84% of owners saying owning pets improved their quality of life¹  – credible stories that could give insight as to why this may be were sourced. 

From a brotherhood like no other between Eric, Peety and Jake; Vale just understanding what Phil was going through without having to speak; a nervous cat called Snowball loving Caroline regardless, no matter what; Brumbi, the bear like dog, picking Helga as his owner to Csenge, Anna’s horse, transforming any bad day – A Unique Bond was born. 
 
In early 2017, Boehringer Ingelheim extended its animal health division. Their growing portfolio and technology platforms are highly competitive in anti-parasitics, vaccines and pharmaceutical specialties in companion animals and livestock. They have also launched value initiatives to highlight the human-animal bond. Through their dedication to animal health, Boehringer Ingelheim is currently the second largest animal health business in the world. 

Dr Maximillian Boost, Head of Digital Communications at Boehringer Ingelheim and the campaign’s lead said: “It is time for us to show everyone what the company is really about – we are about both! The campaign highlights how animals and humans are codependent of one another, connected by this unique bond.”

“Our aim was to give people a reason to believe in our company and its ethos. The campaign has meant that 56% more people now view Boehringer Ingelheim more positively, with three-quarters noting they look to us more favorably than competitors due to our dedication to human and animal health.” 

The campaign’s video content has been well-received by viewers across the globe and resonated with many people, noting that they are “more interested in what Boehringer Ingelheim does.”

Eric Haaksma, Global Head of Research & Development Animal Health Business Unit at Boehringer Ingelheim said “The campaign plays an important role in highlighting the positive impact animals can have in our lives. An example of this positive impact is seen in our ‘Boogie with a Beagle’ project which launched in France. Through this initiative we have encouraged our employees to adopt a dog, which can lead to a healthier lifestyle for them and has a positive effect on both themselves and their new pet. Efforts such as this effectively champion human and animal health and can lead to a higher level of well-being for both” Haaksma added.

A Unique Bond content be seen here: https://www.boehringer-ingelheim.com/corporate-profile/vision-values/a-unique-bond-human-and-animal-health

About Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. 

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales. 

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment. 
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Boehringer Ingelheim Animal Health Business Unit
Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of 3.9 billion euros (2017) and around 10,000 employees worldwide, we are present in more than 150 markets. For more information visit: https://www.boehringer-ingelheim.com/animal-health/overview